Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
BASEL, Switzerland, Jan. 05, 2018 -- Axovant Sciences (NASDAQ:AXON) today announced that its Chief Executive Officer David Hung, MD, will be presenting at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9th at 10:00 a.m. PST at the Westin St. Francis Hotel in San Francisco. In addition, he will participate in a break-out session immediately following the presentation.
A simultaneous webcast will be available in the “Investors” section of the Company’s website at http://investors.axovant.com. A replay of the webcast will be available for 30 days following the live event.
About Axovant Sciences
Axovant is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative medicines to broadly address multiple forms of dementia and related neurological disorders. Axovant is developing a pipeline of product candidates that focuses on the cognitive, functional and behavioral aspects of debilitating conditions such as Alzheimer's disease, Lewy body dementia and other neurological disorders. For more information, visit www.axovant.com.
Contacts:
Investors & Media
Samina Bari
Vice President, Corporate Affairs
[email protected]
[email protected]
Media
Brian Reid
W2O Group
[email protected]
402.875.0525
